Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
196 hedge funds and large institutions have $2.13B invested in Intercept Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 100 increasing their positions, 40 reducing their positions, and 33 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 40
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
12% more call options, than puts
Call options by funds: $103M | Put options by funds: $92M
6% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 33
3% less funds holding
Funds holding: 202 → 196 (-6)
17% less capital invested
Capital invested by funds: $2.57B → $2.13B (-$443M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$62.2M |
| 2 |
JP Morgan Chase
New York
|
+$48M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$39.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.3M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$34.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$72.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$22.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.4M |
| 4 |
Goldman Sachs
New York
|
-$13.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.5M |
ICPT Hedge Fund Activity: Q2 2019 in Review
196 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2019, worth a combined $2.13B — down 17% from $2.57B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ICPT and 31 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 100 added.
The largest buyer was Bellevue Group, adding an estimated $62.2M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $72.5M sold.
- 196 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2019, down from 202 in Q1 2019.
- Funds reported $2.13B of Intercept Pharmaceuticals, Inc. stock for Q2 2019, down 17% quarter-over-quarter.
- 31 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2019 and 33 closed out, a net change of -2 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2019 was Bellevue Group, an estimated $62.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2019 was Point72 Asset Management, an estimated $72.5M sold.
Based on aggregated 13F filings for Q2 2019.